New knee osteoarthritis drug shows promise in early safety trial
NCT ID NCT06263270
First seen Jan 08, 2026 · Last updated May 12, 2026 · Updated 18 times
Summary
This early-stage study tested the safety of an experimental drug called CYT-108 for people with mild to moderate knee osteoarthritis. Nineteen participants received either the drug or a placebo injection into the knee, with a second dose 12 weeks later. Researchers monitored side effects, pain, stiffness, and daily function over 26 weeks to see if the drug is safe and might reduce cartilage breakdown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emeritus Research
Camberwell, Victoria, 3124, Australia
-
Novatrials
Kotara, New South Wales, 2289, Australia
-
University of Sunshine Coast Clinical Trials
Sunshine Coast, Birtinya QLD, 4575, Australia
Conditions
Explore the condition pages connected to this study.